List of Atripla drug patents

Atripla is owned by Gilead Sciences.

Atripla contains Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate.

Atripla has a total of 7 drug patents out of which 0 drug patents have expired.

Atripla was authorised for market use on 12 July, 2006.

Atripla is available in tablet;oral dosage forms.

Atripla can be used as treatment of hiv infection, treatment of hiv-1 infection in pediatric patients 12 years of age and older; treatment of hiv-1 infection in adults, treatment of hiv-1 infection in adults; treatment of hiv-1 infection in pediatric patients 12 years of age and older.

The generics of Atripla are possible to be released after 28 April, 2029.

ATRIPLA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744181 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US8716264 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US8592397 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US9457036 GILEAD SCIENCES Compositions and methods for combination antiviral therapy
Jan, 2024

(9 months from now)

US9545414 GILEAD SCIENCES Unitary pharmaceutical dosage form
Jun, 2026

(3 years from now)

US9018192 GILEAD SCIENCES Unitary pharmaceutical dosage form
Jun, 2026

(3 years from now)

US8598185 GILEAD SCIENCES Unitary pharmaceutical dosage form
Apr, 2029

(6 years from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 12 July, 2006

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv-1 infection in adults

Dosage: TABLET;ORAL

How can I launch a generic of ATRIPLA before it's patent expiration?
More Information on Dosage

ATRIPLA family patents

29

United States

17

Japan

8

European Union

6

China

5

Australia

5

Argentina

4

Hong Kong

4

Norway

4

Korea, Republic of

4

Poland

4

Taiwan, Province of China

EA

4

EA

4

Canada

3

Denmark

3

Slovenia

3

Croatia

3

Portugal

3

Cyprus

3

Spain

3

New Zealand

2

South Africa

2

Austria

2

Mexico

2

Germany

2

Brazil

2

Ukraine

1

Israel

1

Hungary

AP

1

AP

1

Iceland

1

RS

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in